A phase 1/2 study to evaluate the efficacy and safety of HB0025 monotherapy for patients (pts) with advanced renal cell carcinoma (RCC).

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1/2 trial demonstrates promising anti-tumor activity in advanced renal cell carcinoma, suggesting further studies are warranted.

The objective response rate (ORR) was 13.3%, with 2 patients achieving partial responses and 9 having stable disease.
Assessment included 17 enrolled patients, all of whom experienced treatment-related adverse events at some level.
Monotherapy efficacy evaluated using RECIST v.1.1 criteria every 8 weeks, with median follow-up at 5.1 months for some patients enrolled early on in treatment phases. Conditions like proteinuria and hypoalbuminemia were common adverse events affecting the cohort, indicating close monitoring is needed.

Qu et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark